Haleon Targets Weight-Loss Drug Users for U.S. Growth
Haleon plc (NYSE:HLN) is capitalizing on the growing use of GLP-1 weight-loss drugs in the United States by targeting users with products that address related side effects, such as gastrointestinal discomfort. The company has increased sales per store by an average of 24% through dedicated merchandising strategies at CVS stores and other retail locations. Haleon now occupies a significant portion of GLP-1-related shelf space in these outlets. With approximately 11% of Americans using GLP-1 drugs, the market presents a substantial opportunity for over-the-counter products like Tums and Benefiber. Despite early success, broader adoption across retailers is needed to significantly impact Haleon’s overall revenue growth. North America remains strategically important but has historically underperformed, with organic declines in 2025 before showing modest recovery in the first half of 2026.
Topics: consumer health products GLP-1 drugs growth initiatives retail strategy